Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel (Q80585219)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

ChEBI release 2020-05-28

1 reference

Tomasz M Beer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Celestia S Higano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Mansoor Saleh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Robert Dreicer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Gary Hudes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Joel Picus

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Mark Rarick

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Louis Fehrenbacher

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Alison L Hannah

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

7 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

565-570

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17618407%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-007-9068-1

1 January 2020

exact match

0 references

cites work

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

1 reference

12 December 2020

Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

1 reference

12 December 2020

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice

1 reference

12 December 2020

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020